4.7 Article

Dietary compound proanthocyanidins from Chinese bayberry (Myrica rubra Sieb. et Zucc.) leaves inhibit angiogenesis and regulate cell cycle of cisplatin-resistant ovarian cancer cells via targeting Akt pathway

期刊

JOURNAL OF FUNCTIONAL FOODS
卷 40, 期 -, 页码 573-581

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jff.2017.11.045

关键词

Proanthocyanidins; Chinese bayberry leaves; Ovarian cancer; Angiogenesis; Cell cycle; Akt

资金

  1. NIH from the National Center for Research Resources [P20RR016477]
  2. National Institute for General Medical Sciences (NIGMS) [P20GM103434]
  3. NIGMS, a component of the National Institutes of Health (NIH) [P20GM104932]
  4. COBRE [GM102488/RR032138]
  5. ARIA S10 grant [RR020866]
  6. FORTESSA S10 grant [OD016165]
  7. INBRE [GM103434]
  8. National Natural Science Foundation of China [C200501]
  9. National Key Research and Development Program [2016YFD0400805]

向作者/读者索取更多资源

Ovarian cancer is the leading cause of death from gynecological malignancy and natural products have drawn great attention for cancer treatment. Chinese bayberry leaves proanthocyanidin (BLPs) with epigallocatechin-3-gallate (EGCG) as its terminal and major extension units is unusual in the plant kingdom. In the present study, BLPs showed strong growth inhibitory effects on cisplatin-resistant A2780/CP70 cells by inhibiting angiogenesis and inducing G1 cell cycle arrest. BLPs reduced the tube formation in HUVECs and attenuated the wound healing ability in A2780/CP70 cells. BLPs further reduced the level of ROS and targeted Akt/mTOR/p70S6K/4E-BP-1 pathway to reduce the expression of HIF-1 a and VEGF, and thus inhibited angiogenesis. Furthermore, BLPs induced G1 cell cycle arrest by reducing the expressions of c-Myc, cyclin Dl and CDK4, which was also in accordance with the flow cytometry analysis. Overall, these results indicated that BLPs could be a valuable resource of natural compounds for cancer treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据